1 / 53

ARDS The Fundamentals

ARDS The Fundamentals. Objectives. Know the epidemiologic risk factors for ARDS Understand the pathogenesis of lung dysfunction in ARDS Know how to diagnose ARDS Understand the pathophysiology of ARDS Know the principles of management in ARDS Plan mechanical ventilation in ARDS.

hamilton-case
Download Presentation

ARDS The Fundamentals

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. ARDSThe Fundamentals

  2. Objectives • Know the epidemiologic risk factors for ARDS • Understand the pathogenesis of lung dysfunction in ARDS • Know how to diagnose ARDS • Understand the pathophysiology of ARDS • Know the principles of management in ARDS • Plan mechanical ventilation in ARDS

  3. Features of ARDS • Definition: clinically defined hypoxemic respiratory failure • Causes: multiple • Pathophysiology: heterogeneous process mediated by inflammatory pathways • Treatment: identify and treat underlying cause and provide supportive care

  4. DefinitionAmerican-European Consensus Conference (1994) • Require: • 1)Acute onset and persistence of respiratory symptoms • 2) Frontal chest radiograph w/bilateral infiltrates • 3) No clinical evidence of left atrial hypertension (pulmonary capillary wedge <18 mm Hg) • Define: • ALI: P/F ratio <300 mm Hg • ARDS: P/F ratio <200 mm Hg Bernard GR et al., Am J Respir Crit Care Med 1994

  5. Problems with the Definition • Broad definition that does not address cause • What is acute?? • Radiology criteria unspecific • P/F ratio does not account for PEEP or MAP • P/F ratio has not been shown to correlate with the severity of the lung injury, the clinical course, or mortality

  6. Epidemiology • Mortality decreasing • > 50% in mid 80’s • 36% in mid 90’s UpToDate Mortality is still significant

  7. Causes Multifactorial • Direct Lung Injury • Aspiration / chemical pneumonitis • Infectious PNA • Trauma – contusions, penetrating injury, inhalation injury • Near drowning • Fat embolism • Indirect Injury • Inflammation, sepsis • Multiple trauma, burns • Shock, hypoperfusion • Acute pancreatitis • Bypass • Transfusion related

  8. Causes: Children • Shock, sepsis, drowning seem to be top three • In single institution: • Highest incidence (12%) for ARDS was for those with sepsis/viral pneumonia/smoke inhalation/drowning • 2.7% of all admissions developed ARDS.

  9. Risk Factors of Poor Outcome • Clinical • Severity of illness (APACHE) • Other organ involvement, comorbid conditions • Specifically liver dysfunction • Sepsis • Plasma Markers • Acute inflammation (IL-6, IL-8) • Endothelial injury (von Willebrand factor antigen) • Epithelial type II cell molecules (Surfactant protein-D) • Adhesion molecule (Intercellular adhesion molecule-1 (ICAM-1)) • Neutrophil-endothelial interaction (Soluble TNF receptors I and II) • Procoagulant activity (Protein C) • Fibrinolytic activity (Plasminogen activator inhibitor-1) Ware LB. Crit Care Med. 2005

  10. Early deaths (within 72 hours) are caused by the underlying illness or injury, whereas late deaths are caused by sepsis or multiorgan dysfunction

  11. Pathophysiology of ARDS Insult ↓ Activation of inflammatory mediators and cellular components ↓ cytokines (TNF, IL-1, IL-6, IL-8) neutrophil infiltration ↓ damage to capillary endothelial and alveolar epithelial cells

  12. Pathophysiology of ARDS • Starling forces fall out of balance • Increased in capillary hydrostatic pressure • Diminished oncotic pressure gradient • Exudative fluid in both the interstitium and alveoli • impaired gas exchange • decreased compliance • increased pulmonary arterial pressure • Type II pneumocyte damage  decreased surfactant • Loss of aeration (mainly in caudal and dependent lung regions in patients lying supine)

  13. A Picture is Worth a Thousand Words?

  14. The 3 Pathologic Phases of ARDS • Exudative Phase • diffuse alveolar damage • Proliferative Phase • pulm edema resolves • myofibroblasts infiltrate the • interstitium • collagen begins to deposit • Fibrotic Phase • obliteration of normal lung architecture • diffuse fibrosis and cyst formation

  15. Principles of Management • Identify and treat underlying process • Offer supportive care • Improve gas exchange • Trial unproven last ditch therapies No effective modalities to intervene the only therapy that has been proven to be effective at reducing mortality in ARDS in a large, randomized, multi-center, controlled trial is a protective ventilatory strategy

  16. Supportive Care • Sedatives and neuromuscular blockade • Hemodynamic management • Nutritional support • Control of blood glucose levels • VAP and other nosocomial infection prevention • Prophylaxis against DVT and GI bleeding

  17. Sedatives and NMBs • improve tolerance of mechanical ventilation • decrease oxygen consumption BUT • routinely wake patients each day • use intermittent doses when possible • follow a sedation and analgesia protocol

  18. Paralysis: improved oxygenation vs. prolonged neuromuscular weakness • multicenter RCT of ARDS patients - N=340 • cisatracurium vs. placebo drip x 48 hrs • statistically significant decrease in 90-day mortality for subset of patients with P/F < 120 • there was no difference in the frequency of ICU-acquired neuromuscular weakness Papazian L , et al. Neuromuscular blockers in early acute respiratory distress syndrome. NEJM. 2010 Sep;363(12):1107-16

  19. Hemodynamic Management • Decrease oxygen consumption • Because of pulmonary shunting, increasing SvO2 may increase SaO2 • Avoid fever • Avoid anxiety and pain • Avoid excessive use of respiratory muscles • Improve oxygen delivery • CO x (SaO2 x Hgb x 1.34)

  20. Nutrition • ARDS is a catabolic state • Use gut when able • Avoid overfeeding • Keep HOB 30 degrees upright for reflux precautions in intubated patients • Arginine: inhibit platelet aggregation, improve wound healing, changes into NO • Glutamine: fuel for mucosa, lymphocytes, macrophages • PolyUnsaturated Fatty Acids: affect immune balance

  21. VAP • Pulmonary edema is an excellent growth medium for bacteria • Pneumonia is difficult to diagnose • Proven strategies • keep HOB elevated • avoid unnecessary antibiotics • good mouth care • wean vent timely • avoid excessive sedation • vent circuit change per protocol • routine vent tubing care

  22. Improve Gas Exchange • Mechanical ventilator strategies • Use of high fractions of inspired oxygen • Prone positioning

  23. There’s no free lunch!

  24. VILI • Pulmonary edema • Mechanical ventilation alters the alveolar-capillary barrier permeability • Increased transmural vascular pressure • Surfactant inactivation • Mechanical distortion and disruption of endothelial cells • Regional activation of inflammatory cells • Lung inflammation • Repetitive opening /collapse of atelectatic lung units • Surfactant alterations • Loss of alveoli-capillary barrier function • Bacterial translocation • Overinflation of healthy lung regions

  25. Normal – 5 min – 20 min of 45 cmH2O Dreyfuss, Am J Respir Crit Care Med 1998;157:294-323

  26. ARDS Network Study

  27. ARDS Network Study

  28. ARDS Network Study – Other Findings • No difference in their supportive care requirements (vasopressors-IV fluids-fluid balance-diuretics-sedation) • ~10% mortality reduction • Less organ failures • Lower IL-6 and IL-8 levels

  29. Physiologic Effects of Hypercapnia • Resp • Benefits: Improves oxygenation by • Enhancing hypoxic pulmonary vasoconstriction and decreasing intrapulmonary shunting • right-shift of oxygen-hemoglobin dissociation curve • Dangers: • Low PaO2. For a constant FIO2, as the PaCO2 ↑, PAO2 ↓ (alveolar gas equation). • Low pH. (Henderson­Hasselbalch equation) • Decreased ventilatory reserve. Small changes in alveolar ventilation  big change in CO2 when unhealthy

  30. Physiologic Effects of Hypercapnia • Renal: Worsens perfusion by • direct renal vasoconstriction from acidosis and sympathetic-meditated release of NE • But, maintains pH with compensatory bicarb reabsorption • CV: Compromises hemodynamics • Sympathetic stimulation with increased CO • Increased HR and SV, decreased SVR • Intracellular acidosis of cardiomyocytes • When combined with high PEEP strategy, can lead to severely decreased preload and cardiovascular compromise

  31. Permissive HypercapniaIs it worth it? • Early adult ARDS trial showed a reduction in expected mortality of 56% to an actual mortality of 26% • Included in adult trauma patients protocol for mechanical ventilation • Several pediatric studies showing benefit when used in conjunction with low TV and high PEEP Hickling, CCM, 1994 Nathens, J Trauma, 2005 Sheridan, J Trauma, 1995 Paulson, J Pediatr, 1996

  32. PEEP • Improves oxygenation by • Increasing end-expiratory lung volume • Recruiting unventilated alveoli • Decreasing perfusion to unventilated alveoli • Improving V/Q matching • Decreasing intrapulmonary shunt

  33. PVR Increases at Lung Volumes Below and Above FRC Lung Volume

  34. What is adequate PEEP? • Measuring P/V curve is not practical clinically. • A single inflation P/V curve doesn’t represent whole lung. • The P/V curve for the whole lung = sum of multiple regional P/V curves • A lot of variation btwn dependent and nondependent lung

  35. Recruitment Maneuvers • inflating to 40 cm H2O for 15 - 26 seconds • Intermittent increase of PEEP • Sigh breaths When alveolar recruitment is optimized by increasing PEEP, recruitment maneuvers are either poorly effective or deleterious

  36. Proning Proning 7 hrs/day x 10 days Gattinoni, et al AJRCCM 164(9), 1701-11 (2001)

  37. Effects from changes in position • End expiratory views, PEEP 10 • supineprone  supine • Relatively quick change in alveolar gas distribution Gattinoni, et al AJRCCM 164(9), 1701-11 (2001)

  38. ProningHow does it work? • Increases FRC • Improves ventilation of previously dependent regions • Redistribute tidal volume to atelectatic dorsal region • Difference in diaphragm movement: when supine, dorsal and ventral move symmetrically, when prone, dorsal > ventral

  39. Mechanical Ventilation Summary • Avoid overdistension (limit tidal volume and plateau pressure) • Avoid derecruitment (adequate PEEP)

  40. Unproven Therapies for Times of Desperation • Inhaled vasodilators: iNO • Steroids • Beta Agonists • Surfactant • Liquid Ventilation • ECMO

  41. Role of Nitric Oxide in Lung Injury • Optimizes V/Q matching • Inhibits neutrophil adhesion • Effects on long term lung disease unclear

  42. Role of Nitric Oxide in Lung Injury

  43. Steroids in ARDS • Theoretical anti-inflammatory, anti-fibrotic benefit • Inhibit transcriptional activation of various cytokines • Inhibit synthesis of phospholipase A2 : cycloxygenase • Reduced prod. of prostanoids, PAF •  fibrinogenesis • 2 meta-analyses • High dose methylpred for < 48 hrs (30 mg/kg/d) • In early ARDS no benefit LEFERING et al CCM 1995 CRONIN et al., CCM 1995

  44. Steroids in ARDS • Randomized, double-blind, placebo-controlled trial • Adult ARDS ventilated for > 7 days without improvement • No evidence of untreated infection • Randomized: • Placebo • Methylprednisolone 2 mg/kg/day x 14 days, tapered over 1 month Meduri et al, JAMA, 1998

  45. Steroids in ARDS • By day 10, steroids improved: • PaO2/FiO2 ratios • Lung injury scores • Static lung compliance • 24 patients enrolled; study stopped due to survival difference P< 0.01 Meduri et al, JAMA, 1998

  46. Steroids in ARDS ARDSNET 2006:354(16) 1671-83 • N = 180 • Methylpred vs. placebo • > 14 days into course Steroids showed no benefit and some potential adverse effects NOT recommended

  47. Exogenous Surfactant P = 2T/r • Multicenter trial-uncontrolled, observational • Calf lung surfactant (Infasurf) - intratracheal • Immediate improvement and weaning in 24/29 children with ARDS and 14% mortality • In several other studies, there is no evidence for sustained benefit from Surfactant administration Wilson et al, CCM, 24:1996 Wilson et al, JAMA, 2005

  48. Liquid Ventilation • Fill the lungs with liquid – Perfluorocarbon: colorless, odorless, inert, high vapor pressure, oxygen rich liquid • Anti-inflammatory properties (↓ TNF, IL-1 and IL-8, inhibits neutrophil activation and chemotaxis) • Reduces surface tension • ↑ surfactant phospholipid synthesis and secretion • 2 published adult trials of PLV in ARDS have confirmed its safety but not efficacy over HFOV Hirschl et al JAMA 1996, 275; 383-389 Gauger et al, CCM 1996, 24; 16-24

  49. ECMO for Severe Lung Injury • Alternative means for gas exchange • Allows lung rest • May be beneficial in fluid removal • High risk/ high cost venture

  50. Issues with use of ECMO • Is the disease process potentially reversible? • Is there a diagnosis? • Are the pre-ECMO therapies harmful? • Can we prevent iatrogenic complications? • Have we created hemodynamic instability? • Are there other complicating comorbidities? • Will these increase the risk of ECMO? • Requires balancing the risks and benefits

More Related